Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EDAP rises on US trial news:

This article was originally published in Clinica

Executive Summary

EDAP TMS saw its share price rise last week, after announcing that it is fast-tracking the ongoing US trial of its high intensity focused ultrasound (HIFU) treatment for prostate cancer. Its Ablatherm integrated imaging device is designed to target and deliver HIFU energy to the prostate, resulting in thermal destruction of prostate tissue. It is intended for the primary treatment of patients with low risk, localised prostate cancer. The US trial began in April 2006 and is designed to enrol 446 patients. Ablatherm is already approved for sale in the EU, South Korea, Canada and Russia, according to the Vaulx-en-Velin, France-based firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel